MedTrace Logo

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients

NCT02897596 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2019-02-15

No results posted yet for this study

Summary

Evaluate the efficacy of 12 or 8 weeks treatment with Grazoprevir/Elbasvir in Early Chronic Hepatitis C GT1,4 in HIV co-infected patients and evaluate the safety and tolerability of Grazoprevir + Elbasvir in HIV-HCV co-infected patients.

Conditions

  • Hepatitis C
  • HIV

Interventions

DRUG

Grazoprevir 100 mg/d 8 weeks

Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.

DRUG

Elbasvir 50 mg/d 8 weeks

Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.

DRUG

Grazoprevir 100 mg/d 12 weeks

Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.

DRUG

Elbasvir 50 mg/d 12 weeks

Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.

Sponsors & Collaborators

  • Fundacion Clinic per a la Recerca Biomédica

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-28
Primary Completion
2019-04-28
Completion
2019-10-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02897596 on ClinicalTrials.gov